

**Lexington Biosciences, Inc.
Suite 1900, 1055 West Hastings Street
Vancouver, British Columbia, Canada V6E 2E9**

Lexington Biosciences Announces Voluntary Delisting from the CSE

VANCOUVER, BRITISH COLUMBIA – April 30, 2020 - Lexington Biosciences, Inc. (CSE: LNB) (the “Company” or “Lexington”) announces today that the common shares of the Company will be voluntarily delisted from the Canadian Securities Exchange (the “CSE”) at the close of trading on Monday May 4, 2020. Lexington's decision to delist its common shares from the CSE follows the successful vote of the shareholders of the Company in favour of delisting at Lexington's Annual General and Special Meeting of shareholders held on April 24, 2020.

Following the delisting, the Company will proceed with its plans to become a Private Investment Platform Company (the “New Business”).

Once complete, the New Business will allow investors, to use their Registered Plans (including registered retirement savings plans, registered education savings plans, tax free savings accounts, registered retirement income funds, and registered disability savings plans), at their own direction, to invest in private companies by purchasing tracking shares in the Company, which will in turn use these proceeds to invest in the specific private company chosen by the investor.

A portion of an investor's subscription proceeds for tracking shares, as well as a portion of the proceeds from any redemption of tracking shares, will be retained by the Company for administrative and operational expenses.

To reflect the New Business, the Company will be changing its name to “Registered Plan Private Investments Inc.”.

On Behalf of the Board,

“Doug Janzen”

Doug Janzen
Chairman & Director

CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements relating to the delisting from the CSE and the New Business and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include those relating to the ability to launch the New Business and other risks detailed from time to time in the filings made by the Company with securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

CONTACT:

Lexington Biosciences, Inc.

+1 (800) 320-2640

info@lexingtonbiosciences.com

www.lexingtonbiosciences.com